SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Go back to SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease| AbbVie (NYSE: ABBV) | Delayed: 260.31 +3.19 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.12 | 52 Week High | $68.12 | |||
| Open | $261.67 | 52 Week Low | $50.71 | |||
| Day High | $264.65 | P/E | 56.47 | |||
| Day Low | $260.10 | EPS | $4.61 | |||
| Volume | 805,463 | |||||
